Saturday, July 31, 2021 2:51:53 PM
As I stated:
We know for a FACT that Anavex 2-73 Blarcamesine works better in patients with MMSE scores greater than or equal to 20 at baseline.
Alzheimer's disease is easier to treat at the earliest stage possible. See the image below to understand why this is true.
By the way the original Phase 2a trial for Anavex 2-73 Blarcamesine with 32 subjects had a MMSE inclusion range of MMSE score of 16-28 inclusive just like Cassava's current trial.
https://clinicaltrials.gov/ct2/show/NCT02244541
https://clinicaltrials.gov/ct2/show/NCT04388254
Recently Anavex Life Sciences Announced Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
The double-blind, placebo-controlled 450-patient Phase 2b/3 ANAVEX®2-73 clinical study in patients with Alzheimer’s disease exceeded enrollment beyond 450 patients at 52 sites across North America, Europe and Australia using ADAS-Cog (cognition) and ADCS-ADL (activities of daily living and function) as primary endpoints.
https://www.anavex.com/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-anavex2-73-blarcamesine-of-the-phase-2b-3-clinical-trial-in-patients-with-alzheimers-disease/
GOD bless,
We know for a FACT that Anavex 2-73 Blarcamesine works better in patients with MMSE scores greater than or equal to 20 at baseline.
Alzheimer's disease is easier to treat at the earliest stage possible. See the image below to understand why this is true.
By the way the original Phase 2a trial for Anavex 2-73 Blarcamesine with 32 subjects had a MMSE inclusion range of MMSE score of 16-28 inclusive just like Cassava's current trial.
https://clinicaltrials.gov/ct2/show/NCT02244541
https://clinicaltrials.gov/ct2/show/NCT04388254
Recently Anavex Life Sciences Announced Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
The double-blind, placebo-controlled 450-patient Phase 2b/3 ANAVEX®2-73 clinical study in patients with Alzheimer’s disease exceeded enrollment beyond 450 patients at 52 sites across North America, Europe and Australia using ADAS-Cog (cognition) and ADCS-ADL (activities of daily living and function) as primary endpoints.
https://www.anavex.com/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-anavex2-73-blarcamesine-of-the-phase-2b-3-clinical-trial-in-patients-with-alzheimers-disease/
GOD bless,
